SLC16A2 and Allan-Herndon-Dudley syndrome: Recently, the TH analogue 3,3′,5-triiodothyroacetic acid (TRIAC) that exerts thyromimetic actions, but is not dependent on MCT8 for cellular entry, has been suggested as a therapeutic option for AHDS [7,8,9].